0R2M Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0R2M from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$707.30 |
| 52 Week High | US$1,210.92 |
| 52 Week Low | US$693.13 |
| Beta | 0.080 |
| 1 Month Change | -5.60% |
| 3 Month Change | -37.91% |
| 1 Year Change | -16.55% |
| 3 Year Change | 13.10% |
| 5 Year Change | 88.65% |
| Change since IPO | 94.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R2M | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -3.5% | -4.2% | -2.6% |
| 1Y | -16.6% | -24.5% | 2.4% |
Return vs Industry: 0R2M exceeded the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: 0R2M underperformed the UK Market which returned 2.4% over the past year.
Price Volatility
| 0R2M volatility | |
|---|---|
| 0R2M Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0R2M has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0R2M's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 14,165 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
| 0R2M fundamental statistics | |
|---|---|
| Market cap | US$75.51b |
| Earnings (TTM) | US$4.65b |
| Revenue (TTM) | US$13.85b |
16.2x
P/E Ratio5.5x
P/S RatioIs 0R2M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R2M income statement (TTM) | |
|---|---|
| Revenue | US$13.85b |
| Cost of Revenue | US$6.82b |
| Gross Profit | US$7.03b |
| Other Expenses | US$2.37b |
| Earnings | US$4.65b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 43.26 |
| Gross Margin | 50.75% |
| Net Profit Margin | 33.61% |
| Debt/Equity Ratio | 6.8% |
How did 0R2M perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 01:49 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Regeneron Pharmaceuticals, Inc. is covered by 69 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |